Pan-AKT inhibitor ARQ 751

Drug Overview

pan-AKT inhibitor ARQ 751 (also known as vevorisertib) is an investigational, orally bioavailable, second-generation allosteric inhibitor that targets the AKT (protein kinase B) family of serine/threonine kinases. It is specifically designed to potently and selectively inhibit all three major AKT isoforms: AKT1, AKT2, and AKT3.

In the clinical landscape of March 2026, ARQ 751 represents a refined pharmacological approach to “drugging” the PI3K/AKT/mTOR signaling pathway. While first-generation AKT inhibitors often faced challenges with high toxicity (particularly severe hyperglycemia), ARQ 751 was engineered for higher potency and better selectivity. AKT is a central “node” in cellular signaling; when overactive due to mutations (like AKT1-E17K, PIK3CA, or PTEN loss), it drives uncontrolled cell growth and prevents programmed cell death (apoptosis). By binding to AKT in an allosteric fashion—meaning it binds to a site other than the active “pocket”—ARQ 751 prevents the enzyme from ever becoming active. Developed by ArQule (now a subsidiary of Merck & Co., Inc.), the drug is being evaluated for its ability to treat resistant solid tumors that have “exhausted” standard hormone or targeted therapies.

• Generic Name: Pan-AKT inhibitor ARQ 751 (Vevorisertib).
• Code Name: ARQ 751; MK-4440.
• Drug Class: Allosteric pan-AKT Inhibitor.
• Mechanism: Competitive allosteric inhibition of AKT1, 2, and 3, preventing membrane translocation and phosphorylation.
• Route of Administration: Oral (Tablet/Capsule).
• FDA Approval Status: Investigational. As of March 2026, ARQ 751 is not FDA-approved. It is currently being evaluated in Phase 1 and Phase 2 clinical trials for advanced solid tumors.

What Is It and How Does It Work? (Mechanism of Action)

ARQ 751 works by “locking” the AKT protein in an inactive shape, preventing it from receiving the signal to grow.

1. Allosteric Inhibition

Most kinase inhibitors are “ATP-competitive,” meaning they try to crowd out the cell’s energy source from the protein.

• The “Lock” Mechanism: ARQ 751 binds to an allosteric site on the AKT molecule. This induces a structural change that keeps the protein in a “closed” or inactive state.
• Preventing Translocation: For AKT to work, it must move to the cell’s outer membrane. ARQ 751 prevents this movement (translocation), effectively keeping the growth switch in the “off” position.

2. Inhibition of Downstream Signaling

Once ARQ 751 shuts down AKT, the entire “downstream” cascade of the PI3K/AKT/mTOR pathway is silenced.

• Stopping Proliferation: The drug stops the activation of proteins like PRAS40 and GSK3β, which the cell needs to build new proteins and divide.
• Inducing Apoptosis: By blocking survival signals (like BAD and FOXO), ARQ 751 triggers the cancer cell to undergo self-destruction.

3. Targeting the AKT1-E17K Mutation

ARQ 751 is particularly effective against the AKT1-E17K mutation, a “hotspot” genetic error found in some breast and endometrial cancers that makes the AKT protein permanently active. The drug’s allosteric nature allows it to bind even more effectively to this mutated form.

Clinical Indications and Research Status (2026)

In 2026, ARQ 751 is being prioritized for “biomarker-selected” patient populations—those whose tumors have specific genetic “glitches” in the AKT pathway:

• Advanced Solid Tumors (NCT02761694): The primary Phase 1/1b “basket” trial evaluated the drug in patients with PIK3CA, AKT, or PTEN mutations.
• HR+/HER2- Metastatic Breast Cancer: One of the most promising areas of research. ARQ 751 is being studied in combination with fulvestrant (Faslodex) or paclitaxel for patients who have developed resistance to CDK4/6 inhibitors.
• Endometrial Cancer: Because the PTEN/PI3K/AKT pathway is the most frequently mutated pathway in endometrial cancer, ARQ 751 is being evaluated as a way to “re-sensitize” these tumors to chemotherapy.
• Proteus Syndrome and Overgrowth Disorders: While its sibling drug, miransertib (ARQ 092), has been the lead candidate for rare overgrowth diseases, ARQ 751 is being researched as a second-generation option for these patients.

Dosage and Administration Protocols

As an investigational agent, the dosing of ARQ 751 is established through “Dose-Escalation” protocols to find the balance between tumor killing and patient safety.

Clinical Efficacy and Research Results (2024–2026)

Recent data from the Phase 1b expansion cohorts have provided significant insights:

• Antitumor Activity: 2025 results showed that in patients with breast cancer harboring PIK3CA or PTEN mutations, ARQ 751 achieved several Partial Responses (PR) and a high rate of Stable Disease (SD).
• Dose Proportionality: PK studies confirmed that the drug’s levels in the blood increase linearly with the dose, allowing for predictable therapeutic monitoring.
• Target Hit Confirmation: Biopsies from treated patients showed a >80% reduction in the phosphorylation of AKT targets, proving the drug was reaching the tumor and working as intended.

Safety Profile and Side Effects

The side effects of ARQ 751 are largely “on-target” toxicities, as AKT is also involved in how healthy cells process sugar and maintain the skin/mucous membranes.

1. Metabolic Toxicity (Hyperglycemia)

Because AKT is essential for insulin to move sugar out of the blood and into cells, blocking it can cause high blood sugar.

• Symptoms: Increased thirst, frequent urination, and fatigue.
• Management: Often manageable with standard diabetes medications like metformin, though severe cases may require a dose reduction.

2. Gastrointestinal and Mucosal Effects

• Nausea and Vomiting: Reported in roughly 27% of patients.
• Stomatitis/Mucositis: Inflammation and sores in the mouth (Grade 1-2).

3. Skin and General

• Rash and Pruritus: Itching and redness of the skin.
• Fatigue: A common systemic side effect of pathway inhibitors.

Research Areas

In the fields of Stem Cell and Regenerative Medicine, ARQ 751 is being used to study “Metabolic Reprogramming.” Researchers are investigating how “quieting” the AKT pathway can help healthy Stem Cells stay in a protected, dormant state. In 2026, there is also focus on “Immune-Oncology Priming.” Early data suggests that shutting down AKT signaling in the tumor can make it more “visible” to the immune system, potentially making ARQ 751 a future partner for PD-1 inhibitors like pembrolizumab (Keytruda).

Patient Management and Practical Recommendations

Pre-treatment Requirements:

• Molecular Screening: Mandatory testing to confirm PIK3CA, AKT, or PTEN alterations via biopsy or liquid biopsy.
• Baseline Glucose/A1c: Essential for monitoring the risk of hyperglycemia.

“Do’s and Don’ts” List:

• DO monitor your blood sugar regularly if you have a history of pre-diabetes; ARQ 751 can cause a transient rise in glucose levels.
• DO use a mild, alcohol-free mouthwash to prevent the “stomatitis” (mouth sores) often seen with AKT inhibitors.
• DON’T ignore sudden “blurry vision” or “intense thirst,” which could be signs of very high blood sugar (hyperglycemia).
• DON’T take any new “natural supplements” that affect blood sugar (like cinnamon or chromium) without checking with your oncologist first.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. Pan-AKT inhibitor ARQ 751 (vevorisertib) is an investigational agent and is not approved by the U.S. FDA for commercial use. Access is restricted exclusively to registered clinical trials. Always consult with a board-certified oncologist regarding your specific genetic markers and eligibility for AKT-directed clinical research.